Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LAKE FOREST, Ill., Feb. 28, 2017 -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Injection, USP, 500 mg/vial. This approval is the first new product approval received out of Akorn’s Decatur, Illinois manufacturing facility since the FDA re-inspection in December 2016.
According to IMS Health, sales of Mycophenolate Mofetil for Injection were approximately $43 million for the twelve months ended December 31, 2016.
About Akorn
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.
Investors/Media: Stephanie Carrington ICR, Inc. (646) 277-1282 [email protected]
